BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 17210459)

  • 1. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
    Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
    Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
    Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
    Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
    Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides.
    Dijkgraaf I; Kruijtzer JA; Liu S; Soede AC; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):267-73. PubMed ID: 16909226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
    Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
    Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
    Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
    J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.
    Dijkgraaf I; Terry SY; McBride WJ; Goldenberg DM; Laverman P; Franssen GM; Oyen WJ; Boerman OC
    Contrast Media Mol Imaging; 2013; 8(3):238-45. PubMed ID: 23606427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
    Chakraborty S; Shi J; Kim YS; Zhou Y; Jia B; Wang F; Liu S
    Bioconjug Chem; 2010 May; 21(5):969-78. PubMed ID: 20387808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides.
    Zheng Y; Ji S; Tomaselli E; Yang Y; Liu S
    Nucl Med Biol; 2015 Feb; 42(2):137-45. PubMed ID: 25459111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.
    Shi J; Kim YS; Chakraborty S; Zhou Y; Wang F; Liu S
    Amino Acids; 2011 Nov; 41(5):1059-70. PubMed ID: 20052508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides.
    Dijkgraaf I; Yim CB; Franssen GM; Schuit RC; Luurtsema G; Liu S; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):128-37. PubMed ID: 20857099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.
    Cai W; Chen K; Li ZB; Gambhir SS; Chen X
    J Nucl Med; 2007 Nov; 48(11):1862-70. PubMed ID: 17942800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
    Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
    J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
    Ahmadi M; Sancey L; Briat A; Riou L; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP
    Cancer Biother Radiopharm; 2008 Dec; 23(6):691-700. PubMed ID: 19111043
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.